Wexford Capital’s BioAtla BCAB Stock Holding History

Wexford Capital’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-237	Closed	-$29.1K	–	216
2023 Q4	$29.1K	Buy	+237	New	+$20.5K	0.01%	162

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wexford Capital's BCAB Position: Q1 2024 in Review

Wexford Capital sold out of BioAtla (BCAB) in Q1 2024, closing a stake of 237 shares — an estimated $29.1K sold.

Wexford Capital first reported a position in BCAB in Q4 2023 and held it in 1 quarter. The position peaked at $29.1K in Q4 2023. 82 funds tracked by Wall St. Rank hold BCAB as of Q1 2024.

Wexford Capital reported no remaining BioAtla position as of Q1 2024 after selling out during the quarter.
Wexford Capital sold 237 BioAtla shares in Q1 2024, an estimated $29.1K.
Wexford Capital first reported a position in BioAtla in Q4 2023 and held it in 1 quarter.
Wexford Capital's BioAtla position peaked at $29.1K in Q4 2023.
82 funds tracked by Wall St. Rank held BioAtla as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.